Work

Hydroxyprogesterone caproate injection (makena) one year later: to compound or not to compound that is the question.

Year: 2012

Type: article

Abstract: Preterm births have increased by 27% over the last decade in the U.S. The main ingredient in Makena, 17P, is less expensive at compounding pharmacies, but this method is not FDA-approved. The authors discuss the quality, safety, and use of Makena and compounded 17P; the potential for liability; cost considerations; and recommended restrictions for the product's use.

Source: Europe PMC (PubMed Central)

Authors: Yesha Patel, Martha M Rumore

Language: English

Topic: Pharmaceutical studies and practices

Subfield: Pediatrics, Perinatology and Child Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W2128429151

FWCI: 1.775

Cites: 10

Cited by: 19

Related to: 10